The Latest News
Vidacare Corporation has expanded its management team with the hiring of three executives and the promotion of a fourth.
Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced that the first patient initiated treatment in the ARISE trial (Acid Lipase Replacement Investigating Safety and Efficacy), a global, Phase 3, randomized, double-blind, placebo-controlled study of sebelipase alfa in children and adults with late onset lysosomal acid lipase deficiency (LAL Deficiency).
Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced its presentation at the upcoming Leerink Swann Global Healthcare Conference 2013. Mark Goldberg, MD, Senior Vice President, Medical and Regulatory Affairs, is scheduled to present on Wednesday, February 13, 2013, at 9:00 AM EST.
SYNAGEVA BIOPHARMA ANNOUNCES CLOSING OF PUBLIC OFFERING AND EXERCISE OF OPTION TO PURCHASE ADDITIONAL SHARES>
LEXINGTON, Mass., January 9, 2013 -- Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced the closing of a $118 million underwritten public offering of 2,472,500 shares of common stock, including 322,500 shares of common stock which were issued pursuant to the exercise of the underwriters’ option to purchase additional shares, at a price of $47.53 per share.
LOS ANGELES--(BUSINESS WIRE)-- LivHOME CareMonitor™ (www.livhomecaremonitor.com), a remote care service first announced in March, is beginning to roll out nationwide where LivHOME services are offered. It is currently available in Los Angeles, Walnut Creek and Riverside, Calif., and will continue to be rolled out to additional markets in late 2012 and early 2013. LivHOME CareMonitor™ is provided by LivHOME, Inc., one of the nation’s largest providers of professionally led at-home care for seniors.
Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced six month results from an ongoing extension study of sebelipase alfa in adults with late onset Lysosomal Acid Lipase (LAL) Deficiency at the American Association for the Study of Liver Diseases (AASLD) annual meeting being held in Boston, MA, November 9-13, 2012.
The Wall Street Journal announced the winners of its 2012 Technology Innovation Awards today, and for the second time, Vidacare Corporation has been recognized for its ground-breaking technology. Vidacare’s OnControl Bone Marrow System is the overall Bronze winner in this year’s Technology Innovation Awards and the winner of the Medical Devices category. Vidacare’s EZ-IO Intraosseous Infusion System won the overall Gold Technology Innovation of the Year award from the same program in 2008.
On the heels of a recent expanded FDA indication to allow for “bone biopsy of the vertebral body and bone lesions,” Vidacare Corporation’s OnControl Bone Access System has developed a new extension of its technology platform. The OnControl Bone Access System Coaxial Biopsy Tray for powered bone biopsy provides a tool for clinicians to access hard bones and perform biopsies of bone lesions using the company's innovative power-driver and specially engineered needle.
Exagen Diagnostics Inc . said it raised $5.3 million to finance market expansion and development of near-term pipeline products. Tullis Health Investors led the round. Other investors include Cottonwood Technology Fund, Epic Ventures , Mesa Verde Venture Partners and Sun Mountain Capital.
SupplyPro, the premier provider of Point-of-Use (POU) inventory management solutions, today announced the release of two new devices, the SupplyChiller and the SupplyPad.
Estech, a leading provider of minimally invasive cardiac ablation devices, today announced the market release of its COBRA Fusion™ ablation system. This revolutionary technology is the first of its kind to use a unique suction application and innovative electrode configuration to gently pull the tissue targeted for ablation into the device and out of the path of circulating blood.
Vidacare Founder Larry Miller, MD to receive prestigious BioMed SA 2012 Julio Palmaz Award for Innovation in Healthcare and the Biosciences>
In recognition of his contributions to the field of medicine and his pioneering role in using intraosseous vascular access to improve patient care and save lives on a global basis, the Founder and Chief Medical Officer of Vidacare Corporation, Dr. Larry Miller, is the 2012 recipient of the prestigious BioMed SA Julio Palmaz Award for Innovation in Healthcare and the Biosciences.
Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA) today announced the closing of a $115 million underwritten public offering of 2,792,200 shares of common stock, including 364,200 shares of common stock which were issued pursuant to the exercise of the underwriters’ over-allotment option, at a price of $41.20 per share. Morgan Stanley and J.P. Morgan acted as joint book-running managers in the offering, and Cowen and Company, Leerink Swann, Canaccord Genuity Inc. and Wedbush PacGrow Life Sciences acted as co-managers in the offering.
Vidacare Corporation Creates New Medical Director of Clinical Affairs Position for Intraosseous Vascular Access Division>
[San Antonio, Texas] Vidacare Corporation has hired two prominent emergency physicians as Medical Directors of Clinical Affairs. These physicians are joining the newly formed Clinical Affairs Department and will work closely with Emergency Medicine physicians and clinical hospital staff to educate them on the value of incorporating intraosseous vascular access into their practice.Responsibilities will include peer to peer advocacy, education, speaking engagements, subject matter expertise and guidance on practice and hospital adoption of clinical policies for use of the Company's products.
Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA) will present at the Jefferies 2012 Health Care Conference being held in New York City. Carsten Boess, Chief Financial Officer of Synageva, will present on Monday, June 4, 2012, at 11:30 a.m. EDT.
Valeritas Inc. Selects dLife's New Diabetes Patient Engagement Solution For Valeritas' V-go Disposable Insulin Delivery Device>
Valeritas has selected dLife to support its state-of-the-art patient engagement program. dLife, the number-one resource and community network for people living with diabetes, and Valeritas have co-developed V-Go Life, a comprehensive diabetes lifestyle management and support program designed to increase engagement of V-Go users.
With its innovative and simple-to-use insulin delivery device, the V-Go™, Valeritas knows the importance of easy-to-use delivery mechanisms. Its CRM system is no exception. The medical technology company desperately wanted to replace its convoluted, problematic client/server CRM system with something more straightforward to deliver valuable physician information to its commercial teams and vice versa more efficiently. Valeritas turned to cloud-based Veeva CRM and Veeva iRep for the iPad, the same system used by its valued contract sales partner, inVentiv.
Estech Announces FDA Approval to begin Enrollment in ATTAC-AF IDE Trial for the Treatment of Atrial Fibrillation during Cardiac Surgery>
Estech, a leader in minimally invasive and endoscopic cardiac ablation, announced today that the Food and Drug Administration (FDA) has given conditional Investigational Device Exemption (IDE) approval to initiate patient enrollment in the Estech-sponsored ATTAC-AF trial.
Synageva BioPharma and Mitsubishi Tanabe Pharma Corporation Expand Development Collaboration with Second Program>
Synageva BioPharma Corp. (“Synageva”) announced today an expansion of its previous collaboration with Mitsubishi Tanabe Pharma Corporation (Head Office; Osaka, Japan, “MTPC”) to develop a second protein therapeutic for an undisclosed orphan disease using Synageva’s product development capabilities and proprietary protein expression platform.
Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA) today reported 2011 full year financial results and provided 2012 financial guidance. “Strengthened balance sheet enables a focus on key objectives--Adult LAL Deficiency patients continue to enroll into extension study”.